ClinicalTrials.gg
RecruitingNCT06652763MEMRI in HFpEFUpdated Apr 30, 2026

Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction

An observational study in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by University of Leicester · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Diabetes Mellitus, Type 2 by University of Leicester — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Leicester.

Planned enrollment
10th of 11
60 · median 241
Started
2024
with 2 others
Observational
11 of 23
5 open now
Registered
20th of 23
by date

Among the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 20th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, or all of them as a file.
02

Study summary

Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart cannot fill with blood effectively. As a result, people with HFpEF suffer fatigue, breathlessness, and develop swollen limbs. The condition often requires multiple admissions to hospital and is associated with a marked loss of lifespan.

Despite being so common, very little is known about why people develop HFpEF and there are hardly any known treatments. Type 2 diabetes (T2D) is a major risk factor for HFpEF, and people with both HFpEF and diabetes are at a heightened risk of hospitalisation and premature death. It is unclear why the combination of diabetes and HFpEF is particularly harmful. This may be related to the hearts of people with type 2 diabetes being unable to take up the mineral calcium properly, as well as due to their hearts being less energy efficient. Both of these are vital to heart muscle pumping and filling, but until recently it has not been possible to assess these in humans.

New advances in heart MRI scans, with dedicated scanner techniques and dyes (manganese contrast), now allow extremely detailed pictures of heart structure, function, calcium uptake and energy efficiency, all during the same scan. The investigators will enlist 40 volunteers with HFpEF (20 with T2D and 20 without T2D), and up to 20 healthy volunteers, to undergo a heart MRI scan with manganese contrast to assess calcium uptake and energy efficiency. This will allow the comparison of people with HFpEF with and without T2D, to see how their hearts are different to healthy volunteers.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Primary and secondary care patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capacity to provide
  • Symptoms (e.g. breathlessness, orthopnoea, ankle swelling, fatigue), signs (e.g. elevated jugular venous pressure, peripheral oedema, third heart sound) or established diagnosis of HF with LV ≥ 50%, or
  • Meets HFpEF diagnostic criteria in accordance with the HFA-PEFF diagnostic algorithm form the Heart Failure Association of the European Society of Cardiology, in which a score ≥5 points confirms diagnosis of HFpEF

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of Type 1 Diabetes
  • Pregnancy or breast-feeding or females of child bearing age without a negative pregnancy test
  • Receiving an drug or device within 30 days prior to participating in the study
  • Decompensated heart failure or pulmonary oedema
  • History of prolonged interval or torsades de pointes
  • Second- or third-degree atrioventricular block
  • Abnormal liver function tests (> 3x ) or history of liver disease
  • Baseline \< 30mL/min/1.73m2
  • Any to MRI including implanted devices/pacemakers
  • Severe native valve disease, restrictive cardiomyopathy, constrictive pericarditis or hypertrophic cardiomyopathy, myocarditis or takotsubo cardiomyopathy.
  • Recent myocardial infarction within the previous 3 months
  • Known diagnosis of pheochromocytoma
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • HFpEF with T2D

    Participants with heart failure with preserved ejection fraction and type 2 diabetes

    Other: Minnesota Living with Heart Failure Questionnaire · Diagnostic Test: Echocardiogram · Diagnostic Test: Six-minute walk test · Diagnostic Test: Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy · Diagnostic Test: Cardiovascular magnetic resonance scan · Diagnostic Test: Blood tests

  • HFpEF without T2D

    Participants with heart failure with preserved ejection fraction but without type 2 diabetes

    Other: Minnesota Living with Heart Failure Questionnaire · Diagnostic Test: Echocardiogram · Diagnostic Test: Six-minute walk test · Diagnostic Test: Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy · Diagnostic Test: Cardiovascular magnetic resonance scan · Diagnostic Test: Blood tests

  • Controls

    Healthy volunteers without heart failure or type 2 diabetes

    Other: Minnesota Living with Heart Failure Questionnaire · Diagnostic Test: Echocardiogram · Diagnostic Test: Six-minute walk test · Diagnostic Test: Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy · Diagnostic Test: Cardiovascular magnetic resonance scan · Diagnostic Test: Blood tests

Interventions

  • OtherMinnesota Living with Heart Failure Questionnaire

    Self-administered, validated questionnaire to assess symptoms of heart failure

  • Diagnostic testEchocardiogram

    Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain

  • Diagnostic testSix-minute walk test

    Standardised, objective assessment of exercise capacity

  • Diagnostic testManganese-enhanced MRI and 31-P magnetic resonance spectroscopy

    Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).

  • Diagnostic testCardiovascular magnetic resonance scan

    Scan including adenosine stress perfusion

  • Diagnostic testBlood tests

    Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses

06

What researchers measure

Primary outcomes

  1. Ki

    Manganese influx constant as measured by MEMRI scan

    Time frame: Baseline

Secondary outcomes

  1. T1 values

    T1 values measured at 30 minutes post contrast on MEMRI scan

    Time frame: Baseline

  2. Myocardial PCr/ATP ratio

    Phosphocreatine-to-ATP ratio as measured by 31P-magnetic resonance spectroscopy

    Time frame: Baseline

  3. Left ventricular ejection fraction

    %, measured by CMR

    Time frame: Baseline

  4. LV global longitudinal strain

    %, measured by CMR

    Time frame: Baseline

  5. LV global circumferential strain

    %, measured by CMR

    Time frame: Baseline

  6. LV PEDSR

    1/s, measured by CMR

    Time frame: Baseline

  7. LV mass

    grams, measured by CMR

    Time frame: Baseline

  8. LV mass/volume ratio

    Measured by CMR

    Time frame: Baseline

  9. Myocardial fibrosis

    CMR assessed markers of LV myocardial fibrosis (extracellular volume)

    Time frame: Baseline

  10. Myocardial Perfusion

    CMR assessed markers of perfusion (myocardial perfusion reserve)

    Time frame: Baseline

  11. Associations of Ki with resting PCr/ATP

    Univariate and multivariate models to look for association between Ki and PCr/ATP ratio

    Time frame: Baseline

  12. Associations of exercise capacity with Ki and PCr/ATP in HFpEF

    Ki values as assessed by MEMRI, myocardial PCr/ATP as measured by 31P-MRS and six minute walk test distance. Associations will be assessed using univariate and multivariate models.

    Time frame: Baseline

  13. Plasma biomarkers of metabolic dysregulation, fibrosis and inflammation

    This exploratory outcome will assess the differences in a wide range of plasma biomarkers between groups and their association with Ki

    Time frame: Baseline

  14. 10-year outcomes

    10-year outcomes including HF hospitalisation (time to first event and cumulative) and all-cause death.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Nov 2026, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Oct 22, 2024
StartActual
Oct 10, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2036
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06652763
Responsible party
Sponsor
First posted
Oct 22, 2024
Start date
Oct 10, 2024
Primary completion
Nov 2026 (estimated)
Completion
Feb 2036 (estimated)
Last update
Apr 30, 2026

Study contacts

Gerry P McCann, MD
Contact
gpm12@leicester.ac.uk
+44 (0)116 258 3038
Abhishek Dattani, MBBS
Contact
ad530@leicester.ac.uk
Gerry P McCann, MD
principal investigator · University of Leicester
Abhishek Dattani, MBBS
principal investigator · University of Leicester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion